US 11,942,149 B2
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
Liqin Liu, Rockville, MD (US); Chia-Ying Kao Lam, Rockville, MD (US); Gundo Diedrich, Rockville, MD (US); Leslie S. Johnson, Rockville, MD (US); Paul A. Moore, Rockville, MD (US); and Ezio Bonvini, Rockville, MD (US)
Assigned to MACROGENICS, INC., Rockville, MD (US)
Filed by MacroGenics, Inc., Rockville, MD (US)
Filed on Aug. 8, 2022, as Appl. No. 17/883,158.
Application 17/883,158 is a division of application No. 16/488,025, granted, now 11,459,394, issued on Oct. 4, 2022, previously published as PCT/US2018/019188, filed on Feb. 22, 2018.
Claims priority of provisional application 62/597,594, filed on Dec. 12, 2017.
Claims priority of provisional application 62/463,353, filed on Feb. 24, 2017.
Prior Publication US 2022/0406376 A1, Dec. 22, 2022
Int. Cl. G11C 13/00 (2006.01); G11C 15/00 (2006.01)
CPC G11C 13/0026 (2013.01) [G11C 13/004 (2013.01); G11C 15/00 (2013.01); G11C 2013/0045 (2013.01)] 14 Claims
 
1. A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a CD137×TA Binding Molecule; wherein:
the CD137×TA Binding Molecule comprises a CD137 binding domain capable of specific binding to an epitope of CD137; and
the CD137 binding domain comprises a first Light Chain Variable Domain that comprises a CDRL1, CDRL2 and CDRL3, and a first Heavy Chain Variable Domain that comprises a CDRH1, CDRH2 and CDRH3, and:
(A) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(B) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL15 (SEQ ID NO:222); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(C) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL14 (SEQ ID NO:221); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(D) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL11 (SEQ ID NO:218); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(E) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL10 (SEQ ID NO:217); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(F) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL6 (SEQ ID NO:213); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(G) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL4 (SEQ ID NO:211); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or
(H) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VII (SEQ ID NO:74); or
(I) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-4 VL (SEQ ID NO:91); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-4 VII (SEQ ID NO:90); or
(J) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-5 VL (SEQ ID NO:97); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-5 VII (SEQ ID NO:96); or
(K) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1A (SEQ ID NO:83); or
(L) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1C (SEQ ID NO:85); or
(M) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1D (SEQ ID NO:86); and
the CD137×TA Binding Molecule comprises a TA binding domain capable of specific binding to an epitope of a tumor antigen (TA); and
the TA binding domain comprises a second Light Chain Variable Domain that comprises a CDRL1, CDRL2 and CDRL3, and a second Heavy Chain Variable Domain that comprises a CDRH1, CDRH2 and CDRH3; and
wherein the cancer is characterized by the expression of the TA.